2020
Quality of Life With Pembrolizumab for Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: KEYNOTE-040
Harrington KJ, Soulières D, Le Tourneau C, Dinis J, Licitra LF, Ahn MJ, Soria A, Machiels JH, Mach N, Mehra R, Burtness B, Ellison MC, Cheng JD, Chirovsky DR, Swaby RF, Cohen EEW. Quality of Life With Pembrolizumab for Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: KEYNOTE-040. Journal Of The National Cancer Institute 2020, 113: 171-181. PMID: 32407532, PMCID: PMC7850527, DOI: 10.1093/jnci/djaa063.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsCetuximabDisease-Free SurvivalDocetaxelHumansMaleMiddle AgedNeoplasm MetastasisNeoplasm Recurrence, LocalPatient Reported Outcome MeasuresQuality of LifeSquamous Cell Carcinoma of Head and NeckConceptsGHS/QoL scoresStandard of careNeck squamous cell carcinomaGlobal health statusSquamous cell carcinomaQOL scoresWeek 15KEYNOTE-040Metastatic HNSCCCell carcinomaNeck cancer-specific modulePlatinum-containing regimenHealth-related qualityCancer-specific moduleQuality of lifeHRQoL benefitsHRQoL populationMetastatic headHRQoL analysisMedian timeLife HeadPembrolizumabPatientsHealth statusEuropean Organization
2016
CALGB 80403 (Alliance)/E1206: A Randomized Phase II Study of Three Chemotherapy Regimens Plus Cetuximab in Metastatic Esophageal and Gastroesophageal Junction Cancers
Enzinger PC, Burtness BA, Niedzwiecki D, Ye X, Douglas K, Ilson DH, Villaflor VM, Cohen SJ, Mayer RJ, Venook A, Benson AB, Goldberg RM. CALGB 80403 (Alliance)/E1206: A Randomized Phase II Study of Three Chemotherapy Regimens Plus Cetuximab in Metastatic Esophageal and Gastroesophageal Junction Cancers. Journal Of Clinical Oncology 2016, 34: 2736-2742. PMID: 27382098, PMCID: PMC5019745, DOI: 10.1200/jco.2015.65.5092.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAdultAgedAged, 80 and overAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsCamptothecinCarcinoma, Squamous CellCetuximabCisplatinDisease ProgressionDisease-Free SurvivalEpirubicinEsophageal NeoplasmsEsophagogastric JunctionFemaleFluorouracilHumansIrinotecanLeucovorinMaleMiddle AgedOrganoplatinum CompoundsSurvival RateTime FactorsTreatment FailureConceptsGastroesophageal junction cancerProgression-free survivalMetastatic esophagealJunction cancerOverall survivalTreatment failureResponse rateMedian progression-free survivalRandomized phase II studyContinuous infusion fluorouracilOptimal chemotherapy backboneTreatment-related deathsMedian overall survivalPhase II studyPrimary end pointCooperative group studiesPromising preclinical dataChemotherapy backboneChemotherapy regimensAdverse eventsII studySecondary outcomesMedian timeTreatment armsPreclinical data
2012
Effect of increased time from chemoradiation to surgery on the pathologic complete response rate in patients with esophageal cancer.
Shaikh T, Ruth K, Scott W, Burtness B, Cohen S, Konski A, Cooper H, Astsaturov I, Meyer J. Effect of increased time from chemoradiation to surgery on the pathologic complete response rate in patients with esophageal cancer. Journal Of Clinical Oncology 2012, 30: 84-84. DOI: 10.1200/jco.2012.30.4_suppl.84.Peer-Reviewed Original ResearchPathologic complete responseEsophageal cancerPathologic complete response rateT3/T4 lesionsT1/T2 lesionsCarboplatin-based therapyTri-modality treatmentComplete response rateMedian radiation doseType of chemotherapyResectable esophageal cancerMultivariable logistic regressionSquamous cell carcinomaRadiation doseEnd of chemoradiationTrimodality therapyDistant recurrenceSubsequent surgeryT4 lesionsComplete responseMedian ageRectal cancerT2 lesionsMedian timeMultivariable analysis
2009
Phase II trial of docetaxel–irinotecan combination in advanced esophageal cancer
Burtness B, Gibson M, Egleston B, Mehra R, Thomas L, Sipples R, Quintanilla M, Lacy J, Watkins S, Murren JR, Forastiere AA. Phase II trial of docetaxel–irinotecan combination in advanced esophageal cancer. Annals Of Oncology 2009, 20: 1242-1248. PMID: 19429872, PMCID: PMC2699385, DOI: 10.1093/annonc/mdn787.Peer-Reviewed Original ResearchConceptsAdvanced esophageal cancerPartial responseComplete responseEligible patientsEsophageal cancerEastern Cooperative Oncology Group performance statusMetastatic squamous cell carcinomaSafety of docetaxelPhase II trialSquamous cell carcinomaPrincipal toxic effectsAssessable patientsEsophagogastric cancerMeasurable diseaseToxic deathsII trialCN patientsMedian survivalPerformance statusNormal bilirubinPreclinical evidenceMedian timeCell carcinomaMyocardial infarctionTumor assessment
2003
Sequential High‐Dose Alkylating Therapy and Stem Cell Support for High‐Risk Stage III Breast Cancer
Bou‐Khalil J, Rose M, Psyrri A, D’Andrea E, Medoff E, Staugaard‐Hahn C, Holtkamp C, Gran S, Pezzimente J, Snyder E, Cooper D, Haffty B, Reiss M, Burtness B. Sequential High‐Dose Alkylating Therapy and Stem Cell Support for High‐Risk Stage III Breast Cancer. The Breast Journal 2003, 9: 472-477. PMID: 14616941, DOI: 10.1046/j.1524-4741.2003.09604.x.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsConnecticutCyclophosphamideFemaleGranulocyte Colony-Stimulating FactorHumansMedical RecordsMiddle AgedNeoplasm Recurrence, LocalNeoplasm StagingPaclitaxelPalliative CareRetrospective StudiesStem Cell TransplantationSurvival AnalysisTreatment OutcomeConceptsStem cell rescueAdvanced breast cancerBreast cancerCell rescueLymph nodesHormone receptor-positive tumorsIpsilateral axillary lymph nodesStandard-dose adjuvant chemotherapyWhite blood cell toxicityStage III breast cancerAnthracycline-containing chemotherapyPositive lymph nodesTreatment-related complicationsAxillary lymph nodesHigh-dose chemotherapyStem cell supportReceptor-positive tumorsGranulocyte colony-stimulating factorMajority of cancersColony-stimulating factorAdjuvant chemotherapyNeutropenic feverNeoadjuvant chemotherapyStage IIIBMedian time
2000
Transplantation of CD34+ peripheral blood cells selected using a fully automated immunomagnetic system in patients with high-risk breast cancer: results of a prospective randomized multicenter clinical trial
Yanovich S, Mitsky P, Cornetta K, Maziarz R, Rosenfeld C, Krause D, Lotz J, Bitran J, Williams S, Preti R, Somlo G, Burtness B, Mills B. Transplantation of CD34+ peripheral blood cells selected using a fully automated immunomagnetic system in patients with high-risk breast cancer: results of a prospective randomized multicenter clinical trial. Bone Marrow Transplantation 2000, 25: 1165-1174. PMID: 10849529, DOI: 10.1038/sj.bmt.1702415.Peer-Reviewed Original ResearchConceptsHigh-risk breast cancer patientsBreast cancer patientsMedian timeCancer patientsIsolated CD34Clinical trialsCell selection systemHematopoietic reconstitutionHigh-risk breast cancerCapacity of CD34Transplantation of CD34Absolute neutrophil countDuration of hospitalizationHigh-dose chemotherapyMulticenter clinical trialBone Marrow Transplantation (2000) 25Incidence of infectionPeripheral blood cellsInter-group differencesProgenitor cell graftsPlatelet engraftmentNeutrophil countCell transplantPlatelet transfusionsPlatelet count